Method of inhibiting binding or activity of MIF by administering a MIF antagonist
US-9221903-B2 · Dec 29, 2015 · US
Method for measuring ATR inhibition mediated increases in DNA damage
US8999632B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8999632-B2 |
| Application number | US-201314045373-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 3, 2013 |
| Priority date | Oct 4, 2012 |
| Publication date | Apr 7, 2015 |
| Grant date | Apr 7, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present relates to methods for detecting DNA damage in subjects treated with an ATR inhibitor. More specifically, this invention relates to a method for measuring changes in levels of γH2AX and/or pChk1 Ser345 in, e.g., surrogate tissue cells, following ex vivo stimulation with a DNA damaging agent.
First claim
Opening claim text (preview).
We claim: 1. A method for monitoring DNA damage in a subject by measuring accumulation of γH2AX from blood, the method comprising: a) treating a subject with an ATR inhibitor; b) taking blood samples from the subject at various intervals; c) treating the blood samples with a DNA damaging agent; d) isolating white blood cells from the blood samples; and e) measuring γH2AX levels in the white blood cells by using antibodies specific for γH2AX. 2. The me…
Assignees
Inventors
Classifications
- G01N33/5047Primary
Physics · mapped topic
Physics · mapped topic
- G01N33/6875Primary
Physics · mapped topic
Physics · mapped topic
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8999632B2 cover?
- The present relates to methods for detecting DNA damage in subjects treated with an ATR inhibitor. More specifically, this invention relates to a method for measuring changes in levels of γH2AX and/or pChk1 Ser345 in, e.g., surrogate tissue cells, following ex vivo stimulation with a DNA damaging agent.
- Who is the assignee on this patent?
- Vertex Pharma, Univ Newcastle
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5047. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Apr 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).